Impaired response to immunotherapy in NASH-driven HCC is associated with reduced motility and abnormal metabolic functions of CD8+ T cells rather than infiltration of CD8+ T cells and concentration of effector CD8+ T cells in tumor tissue (147, 148). Here, CD8A is linked to metabolic dysfunction-associated steatohepatitis.